SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
SARS-CoV-2 from alpha to epsilon: As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of concern because they are resistant to antibodies elicited by infection or vaccination or they increase transmissibility or disease severity. Three papers used functional and structural studies to explore how mutations in the viral spike protein affect its ability to infect host cells and to evade host immunity. Gobeil et al . looked at a variant spike protein involved in transmission between minks and humans, as well as the B1.1.7 (alpha), B.1.351 (beta), and P1 (gamma) spike variants; Cai et al . focused on the alpha and beta variants; and McCallum et al . discuss the properties of the spike protein from the B1.1.427/B.1.429 (epsilon) variant. Together, these papers show a balance among mutations that enhance stability, those that increase binding to the human receptor ACE2, and those that confer resistance to neutralizing antibodies. —VV
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2. B.1.427/B.1.429 S pseudotyped virus neutralization by vaccine-elicited and COVID-19 convalescent plasma. (A, B, E, and F) Neutralizing Ab titers [mean inhibition dilution (ID50)] shown as pairwise connected [(A) and (E)] or GMT [(B) and (F)] against MLV [(A) and (B)] or VSV [(E) and (F)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Moderna mRNA-1273 vaccine (blue). (C, D, G, and H) Neutralizing Ab titers (ID50) shown as pairwise connected [(C) and (G)] or GMT [(D) and (H)] against MLV [(C) and (D)] or VSV [(G) and (H)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine (red). (I and J) Neutralizing Ab ID50 (I) and GMT (J) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from naïve (blue) and previously infected (red) individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine. “Naïve” indicates vaccinated individuals who had not been previously infected with SARS-CoV-2; “immune” refers to vaccinated individuals who had been previously infected with SARS-CoV-2. (K and L) Neutralizing Ab ID50 (K) and GMT (L) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from convalescent individuals who were infected with WT SARS-CoV-2. Neutralization data shown in (A) to (H) and (I) to (L) were performed using 293T-ACE2 and VeroE6-TMPRSS2, respectively. Data are average of n = 2 replicates.](https://figures.cochat.ai/paper-figures/e2b6f8f874fc4753bb3a1e70b39ac8ee/sars-cov-2-immune-evasion-by-the-b-1-427-b-1-429-variant-of-concern-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This signal peptide modification resulted in a total loss of neutralization by ten NTD-specific antibodies [40].”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of 34 convalescent plasma samples from persons infected with the Alpha variant, 59% had 3-fold to 10-fold reduced neutralizing activity and 18% had >10-fold reduced neutralizing activity to the Beta variant 99,104,221 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [221]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A novel mechanism of immune evasion was studied in the Epsilon variant, where the other two mutations remodeled NTD by shifting the signal peptide cleavage site in the NTD antigenic supersite and forming a new disulfide bond.”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Self-citationLiebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J., Lindahl, E., & Scheres, S. H. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,621
Cited by
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03944-y · Cited by 1,337
Self-citationBroadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., De Marco, A., di Iulio, J., et al. (2022) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,080
“46 McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332-2347 e2316, doi:10.1016/j.cell.2021.03.028 (2021). 47 Fischer, W. et al. HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host Microbe 29, 1093-1110, doi:10.1016/j.ch…”
InfluentialSelf-citationThe biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
The immunology and immunopathology of COVID-19
Merad, M., Blish, C. A., Sallusto, F., & Iwasaki, A. (2022) · Science · doi:10.1126/science.abm8108 · Cited by 751
Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., Panda, S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9071542 · Cited by 730
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669
Geers, D., Shamier, M. C., Bogers, S., den Hartog, G., Gommers, L., Nieuwkoop, N. N., Schmitz, K. S., Rijsbergen, L. C., van Osch, J. A. T., Dijkhuizen, E., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj1750 · Cited by 529
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
McCallum, M., Czudnochowski, N., Rosen, L. E., Zepeda, S. K., Bowen, J. E., Walls, A. C., Hauser, K., Joshi, A., Stewart, C., Dillen, J. R., et al. (2022) · Science · doi:10.1126/science.abn8652 · Cited by 535
Self-citationSARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Starr, T. N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y.-J., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03807-6 · Cited by 515
Self-citationCOVID-19 vaccine development: milestones, lessons and prospects
Li, M., Wang, H., Tian, L., Pang, Z., Yang, Q., Huang, T., Fan, J., Song, L., Tong, Y., & Fan, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00996-y · Cited by 434
“5 times compared to the wild type.(116) Furthermore, more than 50% of mRNA-1273 recipients’ serum failed to neutralize the Omicron variant, with the GMTs reduced by about 43 times.”
BackgroundBroad betacoronavirus neutralization by a stem helix–specific human antibody
Pinto, D., Sauer, M. M., Czudnochowski, N., Low, J. S., Tortorici, M. A., Housley, M. P., Noack, J., Walls, A. C., Bowen, J. E., Guarino, B., et al. (2021) · Science · doi:10.1126/science.abj3321 · Cited by 388
Self-citationTackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 383
Self-citationNovel SARS-CoV-2 variants: the pandemics within the pandemic
Boehm, E., Kronig, I., Neher, R. A., Eckerle, I., Vetter, P., & Kaiser, L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.022 · Cited by 345
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Hastie, K. M., Li, H., Bedinger, D., Schendel, S. L., Dennison, S. M., Li, K., Rayaprolu, V., Yu, X., Mann, C., Zandonatti, M., et al. (2021) · Science · doi:10.1126/science.abh2315 · Cited by 314
Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
Dhar, M. S., Marwal, R., VS, R., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., et al. (2021) · Science · doi:10.1126/science.abj9932 · Cited by 296
Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
Dhar, M. S., Marwal, R., Radhakrishnan, V., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., et al. (2021) · doi:10.1101/2021.06.02.21258076 · Cited by 296
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
McCallum, M., Walls, A. C., Sprouse, K. R., Bowen, J. E., Rosen, L. E., Dang, H. V., De Marco, A., Franko, N., Tilles, S. W., Logue, J., et al. (2021) · Science · doi:10.1126/science.abl8506 · Cited by 288
“In both structures, the L452R side chain, which is part of antigenic site Ib (18), is oriented identically (and modeled in the same rotameric configuration) to what we previously observed in the B.1.427/B.1.429 S structure (52) (Fig 2E-F).”
InfluentialSelf-citationMonoclonal antibody therapies against SARS-CoV-2
Focosi, D., McConnell, S., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 269
Broad sarbecovirus neutralization by a human monoclonal antibody
Tortorici, M. A., Czudnochowski, N., Starr, T. N., Marzi, R., Walls, A. C., Zatta, F., Bowen, J. E., Jaconi, S., Di Iulio, J., Wang, Z., et al. (2021) · Nature · doi:10.1038/s41586-021-03817-4 · Cited by 266
Self-citationBroadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/d41586-021-03825-4 · Cited by 254
Self-citationGreaney, A. J., Loes, A. N., Gentles, L. E., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9915 · Cited by 244
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
Martínez-Flores, D., Zepeda-Cervantes, J., Cruz-Reséndiz, A., Aguirre-Sampieri, S., Sampieri, A., & Vaca, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701501 · Cited by 240
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Hwang, Y.-C., Lu, R.-M., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H.-C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 237
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
Oude Munnink, B. B., Worp, N., Nieuwenhuijse, D. F., Sikkema, R. S., Haagmans, B., Fouchier, R. A. M., & Koopmans, M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01472-w · Cited by 231
Impact of the delta variant on vaccine efficacy and response strategies
Bian, L., Gao, Q., Gao, F., Wang, Q., He, Q., Wu, X., Mao, Q., Xu, M., & Liang, Z. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1976153 · Cited by 219
“In addition, this mutation can cause the vaccine-induced serum neutralizing antibody titer against the pseudovirus to decrease by 3–6 times [20,21], and the pseudovirus can escape many authorized monoclonal antibodies [21,22].”
BackgroundTchesnokova, V., Kulasekara, H., Larson, L., Bowers, V., Rechkina, E., Kisiela, D., Sledneva, Y., Choudhury, D., Maslova, I., Deng, K., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00921-21 · Cited by 217
“In particular, one study has shown that the L452R mutation reduced neutralizing activity of 14 of 34 RBDspecific monoclonal antibodies (16).”
BackgroundStructural diversity of the SARS-CoV-2 Omicron spike
Gobeil, S. M.-C., Henderson, R., Stalls, V., Janowska, K., Huang, X., May, A., Speakman, M., Beaudoin, E., Manne, K., Li, D., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.028 · Cited by 210
“Structural studies have been instrumental in revealing changes in VOC S protein conformations, and in understanding the atomic level mechanisms that drive higher transmissibility and immune evasion (5-9).”
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel‐Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W., Porrot, F., Staropoli, I., Lemoine, F., et al. (2021) · Nature · doi:10.1038/d41586-021-03827-2 · Cited by 197
Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe
Thakur, V., Bhola, S., Thakur, P., Patel, S. K. S., Kulshrestha, S., Ratho, R. K., & Kumar, P. (2022) · Infection · doi:10.1007/s15010-021-01734-2 · Cited by 195
The humoral response and antibodies against SARS-CoV-2 infection
Qi, H., Liu, B., Wang, X., & Zhang, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01248-5 · Cited by 191
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2021) · Biomolecules · doi:10.3390/biom11070993 · Cited by 188
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
Davis, C., Logan, N., Tyson, G., Orton, R., Harvey, W. T., Perkins, J. S., Mollett, G., Blacow, R. M., The COVID-19 Genomics UK (COG-UK) Consortium, Peacock, T. P., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1010022 · Cited by 187
“429, a variant of interest (VOI) first identified in California and associated with reduced neutralisation titres with plasma from vaccinated or convalescent individuals [7].”
BackgroundWalls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.015 · Cited by 185
Self-citationWang, Y., Liu, C., Zhang, C., Wang, Y., Hong, Q., Xu, S., Li, Z., Yang, Y., Huang, Z., & Cong, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-28528-w · Cited by 180
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
Bowen, J. E., Addetia, A., Dang, H. V., Stewart, C., Brown, J. T., Sharkey, W. K., Sprouse, K. R., Walls, A. C., Mazzitelli, I. G., Logue, J. K., et al. (2022) · Science · doi:10.1126/science.abq0203 · Cited by 166
Self-citationEmerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
Ramesh, S., Govindarajulu, M., Parise, R. S., Neel, L. T., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., & Moore, T. (2021) · Vaccines · doi:10.3390/vaccines9101195 · Cited by 176
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion
Ferreira, I. A. T. M., Kemp, S. A., Datir, R., Saito, A., Meng, B., Rakshit, P., Takaori-Kondo, A., Kosugi, Y., Uriu, K., Kimura, I., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab368 · Cited by 151
“429 and is associated with increase in viral load and around 20% increased transmissibility [3].”
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Kreuzberger, N., Hirsch, C., Chai, K. L., Tomlinson, E., Khosravi, Z., Popp, M., Neidhardt, M., Piechotta, V., Salomon, S., Valk, S. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013825.pub2 · Cited by 169
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Kleanthous, H., Silverman, J. M., Makar, K. W., Yoon, I.-K., Jackson, N., & Vaughn, D. W. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 139
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
Park, Y.-J., De Marco, A., Starr, T. N., Liu, Z., Pinto, D., Walls, A. C., Zatta, F., Zepeda, S. K., Bowen, J. E., Sprouse, K. R., et al. (2022) · Science · doi:10.1126/science.abm8143 · Cited by 140
Self-citationMolecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Sun, C., Xie, C., Bu, G., Zhong, L., & Zeng, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01039-2 · Cited by 164
Antibody and B cell responses to SARS-CoV-2 infection and vaccination
Röltgen, K., & Boyd, S. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.009 · Cited by 158
SARS‐CoV‐2 variants and vulnerability at the global level
Chavda, V. P., Patel, A., & Vaghasiya, D. D. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27717 · Cited by 145
“W152C has been shown to diminish sensitivity to numerous NTD‐binding monoclonal antibodies, implying yet another involvement in immune evasion.(76) Currently, it is considered a VOI.”
BackgroundAn intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Hassan, A. O., Shrihari, S., Gorman, M. J., Ying, B., Yuan, D., Raju, S., Chen, R. E., Dmitriev, I. P., Kashentseva, E. A., Adams, L. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109452 · Cited by 138
“As seen with vaccine-induced human sera against some variant viruses (Chen et al., 2021; McCallum et al., 2021; Tada et al., 2021; Wang et al., 2021a, 2021b; Wibmer et al., 2021), we observed decreases in neutralizing titers against Wash-B.”
Hunt, A. C., Case, J. B., Park, Y.-J., Cao, L., Wu, K., Walls, A. C., Liu, Z., Bowen, J. E., Yeh, H.-W., Saini, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1252 · Cited by 120
Self-citationCOVID-19 Diagnosis: A Comprehensive Review of the RT-qPCR Method for Detection of SARS-CoV-2
Dutta, D., Naiyer, S., Mansuri, S., Soni, N., Singh, V., Bhat, K. H., Singh, N., Arora, G., & Mansuri, M. S. (2022) · Diagnostics · doi:10.3390/diagnostics12061503 · Cited by 172
“427 March 2020 United States 5 March 2021 [57,58]”
BackgroundSARS-CoV-2: Evolution and Emergence of New Viral Variants
Flores-Vega, V. R., Monroy-Molina, J. V., Jiménez-Hernández, L. E., Torres, A. G., Santos, J. I., & Rosales-Reyes, R. (2022) · Viruses · doi:10.3390/v14040653 · Cited by 143
“3-fold reduction was observed with the Pfizer-BioNTech vaccine [60].”
MethodRecurrent SARS-CoV-2 mutations in immunodeficient patients
Wilkinson, S., Richter, A. G., Casey, A., Osman, H. K. E., Mirza, J. D., Stockton, J., Quick, J., Ratcliffe, L., Sparks, N., Cumley, N., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac050 · Cited by 134
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
Hillary, V. E., & Ceasar, S. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13952 · Cited by 131
HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens
Fischer, W. M., Giorgi, E. E., Chakraborty, S., Nguyen, K., Bhattacharya, T., Theiler, J. P., Goloboff, P. A., Yoon, H., Abfalterer, W., Foley, B. T., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.012 · Cited by 114
Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions
Dhawan, M. K., Sharma, A., Choudhary, P., Thakur, N., Rajkhowa, T. K., & Choudhary, O. P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2068883 · Cited by 127
“Moreover, L452R mutation can cause the vaccine-induced serum neutralizing antibody titer against the pseudovirus to decrease by 3–6 times(39,41) and the pseudovirus can evade several permitted MAbs based therapeutics.(41,42)”
BackgroundSignatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 106
A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines
Ghasemiyeh, P., Mohammadi‐Samani, S., Firouzabadi, N., Dehshahri, A., & Vazin, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108162 · Cited by 105
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
Díaz-Salinas, M. A., Li, Q., Ejemel, M., Yurkovetskiy, L., Luban, J., Shen, K., Wang, Y., & Munro, J. B. (2022) · eLife · doi:10.7554/elife.75433 · Cited by 87
“As S309 does not prevent ACE2 binding, its mechanism of broad neutralization remains unclear ( McCallum et al., 2021a ; Pinto et al., 2020 ).”
Tortorici, M. A., Walls, A. C., Joshi, A., Park, Y., Eguia, R. T., Miranda, M. C., Kepl, E., Dosey, A. M., Stevens‐Ayers, T., Boeckh, M. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.019 · Cited by 95
“…immune evasion, replication kinetics or disease severity relative to the ancestral SARS-CoV-2 isolate (Cele et al., 2021; Collier et al., 2021; Davies et al., 2021; Edara et al., 2021; Liu et al., 2021a, 2021b; McCallum et al., 2021a, 2021b; Plante et al., 2020; Wibmer et al., 2021).”
Self-citationBaral, P., Bhattarai, N., Hossen, M. L., Stebliankin, V., Gerstman, B. S., Narasimhan, G., & Chapagain, P. P. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.036 · Cited by 98
Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern
Kim, S., Liu, Y., Lei, Z., Dicker, J., Cao, Y., Zhang, X. F., & Im, W. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00965 · Cited by 91
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Ying, B., Whitener, B., VanBlargan, L. A., Hassan, A. O., Shrihari, S., Liang, C.-Y., Karl, C. E., Mackin, S., Chen, R. E., Kafai, N. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3302 · Cited by 85
Spike-heparan sulfate interactions in SARS-CoV-2 infection
Kearns, F. L., Sandoval, D. R., Casalino, L., Clausen, T. M., Rosenfeld, M. A., Spliid, C. B., Amaro, R. E., & Esko, J. D. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102439 · Cited by 89
Salleh, M. Z., Derrick, J. P., & Deris, Z. Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147425 · Cited by 88
Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
Dubey, A., Choudhary, S., Kumar, P., & Tomar, S. (2021) · Current Microbiology · doi:10.1007/s00284-021-02724-1 · Cited by 85
Evolution of pathogen tolerance and emerging infections: A missing experimental paradigm
Seal, S., Dharmarajan, G., & Khan, I. (2021) · eLife · doi:10.7554/elife.68874 · Cited by 90
“429), isolated from California (USA), was also found to harbor spike glycoprotein mutation that could reduce the neutralization effectivity of the Wuhan-1 isolatebased mRNA vaccine (McCallum et al., 2021), suggesting the possibility of new mutations aiding rapid evolution of the virus against vaccineelicited antibodie…”
BackgroundStructural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain
Smith, K. N., Clark, S. A., Shankar, S., Pan, J., Clark, L. E., Yang, P., Coscia, A., McKay, L. G. A., Varnum, H., Brusic, V., et al. (2022) · Science · doi:10.1126/science.abl6251 · Cited by 83
“Additionally, starting with the Beta variant spike protein sequence, we generated a variant pseudotype that contains two additional mutations associated with immune evasion (L452RRBD and N439KRBD) (40, 41).”
MethodInfluentialWang, C. Y., Hwang, K.-P., Kuo, H.-K., Peng, W.-J., Shen, Y.-H., Kuo, B.-S., Huang, J.-H., Liu, H., Ho, Y.-H., Lin, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157707 · Cited by 87
“L452R is located within an epitope for several neutralizing antibodies (54, 55), whereas T478K is unique to the Delta variant (56) and centrally located within the ACE2 binding site, affecting its binding affinity (57).”
Rotondo, J. C., Martini, F., Maritati, M., Mazziotta, C., Mauro, G. D., Lanzillotti, C., Barp, N., Gallerani, A., Tognon, M. G., & Contini, C. (2021) · Viruses · doi:10.3390/v13091687 · Cited by 88
Bowen, J. E., Park, Y., Stewart, C., Brown, J. T., Sharkey, W. K., Walls, A. C., Joshi, A., Sprouse, K. R., McCallum, M., Tortorici, M. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.adf1421 · Cited by 86
“…of the SARS-CoV-2 NTD among variants and sarbecoviruses, which is associated with a narrow specificity of NTD neutralizing antibodies ( 25 , 28 , 66 , 73 , 75 , 76 ), and (ii) the description of multiple broadly neutralizing sar-becovirus antibodies recognizing distinct RBD antigenic sites ( 14…”
Self-citationSARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines
Khan, A., Khan, T., Ali, S., Aftab, S., Wang, Y., Wang, Q., Khan, M., Suleman, M., Ali, S., Heng, W., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112176 · Cited by 78
Cerutti, G., Guo, Y., Wang, P., Nair, M. S., Wang, M., Huang, Y., Yu, J., Liu, L., Katsamba, P. S., Bahna, F., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109928 · Cited by 72
COVID-19 Mechanisms in the Human Body—What We Know So Far
Kumar, A., Narayan, R. K., Prasoon, P., Kumari, C., Kaur, G., Kumar, S., Kulandhasamy, M., Sesham, K., Pareek, V., Faiq, M. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693938 · Cited by 82
Multivalent 9-O-Acetylated-sialic acid glycoclusters as potent inhibitors for SARS-CoV-2 infection
Petitjean, S. J. L., Chen, W., Koehler, M., Jimmidi, R., Yang, J., Mohammed, D., Juniku, B., Stanifer, M. L., Boulant, S., Vincent, S. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30313-8 · Cited by 80
Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105370 · Cited by 77
Mutations in SARS-CoV-2 structural proteins: a global analysis
Abavisani, M., Rahimian, K., Mahdavi, B., Tokhanbigli, S., Sisakht, M. M., Farhadi, A., Kodori, M., Mahmanzar, M., & Meshkat, Z. (2022) · Virology Journal · doi:10.1186/s12985-022-01951-7 · Cited by 79
“Some S protein mutations, such as E484K and L452R, reduce antibody sensitivity and require higher convalescent sera titers for neutralization [10, 46, 47].”
BackgroundThe inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein
Dokainish, H. M., Re, S., Mori, T., Kobayashi, C., Jung, J., & Sugita, Y. (2022) · eLife · doi:10.7554/elife.75720 · Cited by 71
Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 70
SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
Tatsi, E., Filippatos, F., & Michos, A. G. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002430 · Cited by 77
“D614G ↑Transmissibility [14] ↓Resistance to Abs from convalescent serum [14, 56] ↓↓Neutralizing activity with BNT162b2 and mRNA-1273 [42, 56] No differences in neutralizing activity with CoronaVac [109] 66% for Ad26.”
BackgroundMannar, D., Saville, J. W., Sun, Z., Zhu, X. Q., Martí, M. M., Srivastava, S. S., Berezuk, A., Zhou, S., Tuttle, K. S., Sobolewski, M. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32262-8 · Cited by 68
One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 69
A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein
Ghosh, N., Nandi, S., & Saha, I. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108565 · Cited by 70
Jhun, H., Park, H., Hisham, Y., Song, C., & Kim, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e32 · Cited by 67
“The US FDA recommends using the alternative authorized monoclonal Ab therapies because no impact or susceptibility to EUA monoclonal Ab treatments providing a minimal impact on neutralization by convalescent and post-vaccination sera (40,46,50,55-58,61,62).”
BackgroundMethodCarreño, J. M., Alshammary, H., Singh, G., Raskin, A. J., Amanat, F., Amoako, A. A., Gonzalez-Reiche, A. S., van de Guchte, A., PARIS study group, Awawda, M. H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103626 · Cited by 63
“These include Iota (B. 1.526) which emerged in New York City and comprises three different sub-lineages [10,11], Epsilon (B.1.427/ B.1.429) which emerged in California [12], Lambda (C.37) which emerged in Peru (preprint [13]), Delta (B.1.617.2) and Kappa (B.1.617.1) which emerged in India [14], B.1.1.7 carrying E484K…”
InfluentialA SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
Greaney, A. J., Starr, T. N., Eguia, R. T., Loes, A. N., Khan, K., Karim, F., Cele, S., Bowen, J. E., Logue, J. K., Corti, D., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010248 · Cited by 62
Self-citationThe antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
Liu, C., Zhou, D., Nutalai, R., Duyvesteyn, H. M. E., Tuekprakhon, A., Ginn, H. M., Dejnirattisai, W., Supasa, P., Mentzer, A. J., Wang, B., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.11.013 · Cited by 66
SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
Alkhatib, M., Svicher, V., Salpini, R., Ambrosio, F. A., Bellocchi, M. C., Carioti, L., Piermatteo, L., Scutari, R., Costa, G., Artese, A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01096-21 · Cited by 65
“several NTD-targeting monoclonal antibodies, suggesting a potential role in immune escape (26).”
BackgroundKlinakis, A., Cournia, Z., & Rampias, T. N. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.10.004 · Cited by 61
“In the Epsilon (B.1.427/B.1.429) strain, an alternative disulfide bond between C136 and W152C is proposed to drive NTD conformational changes that lead to immune escape from NTD targeting neutralizing antibodies [34].”
InfluentialDevelopment and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Yilmaz, I. C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Guvencli, N., Aydin, Y., Gungor, B., et al. (2021) · Allergy · doi:10.1111/all.15091 · Cited by 66
Bradley, B. T., Bryan, A. B., Fink, S. L., Goecker, E. A., Roychoudhury, P., Huang, M.-L. W., Zhu, H., Chaudhary, A., Madarampalli, B., Lu, J., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00989-21 · Cited by 56
SARS-CoV-2 Omicron variant emerged under immune selection
Tan, C. W., Chia, W. N., Zhu, F., Young, B. E., Chantasrisawad, N., Hwa, S.-H., Yeoh, A. Y.-Y., Lim, B. L., Yap, W. C., Pada, S., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01246-1 · Cited by 58
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
Ryu, D.-K., Song, R., Kim, M., Kim, Y., Kim, C.-M., Kim, J., Kwon, K.-S., Tijsma, A. S. L., Nuijten, P. M., van Baalen, C. A., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.06.016 · Cited by 58
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 58
“The purpose of vaccination is to induce an immune response similar to natural infection and to produce associated immune cells and antibodies, and the antibody response caused by the vaccine is stronger than that caused by natural infection (36).”
BackgroundInfluentialEmerging SARS-CoV-2 Variants Can Potentially Break Set Epidemiological Barriers in COVID-19
Kumar, A., Parashar, R., Kumar, S., Faiq, M. A., Kumari, C., Kulandhasamy, M., Narayan, R. K., Jha, R. K., Singh, H. N., Prasoon, P., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27467 · Cited by 55
“formational changes at the binding interface, (ii) remodeling of the electrostatic surface potential, and (iii) gain of additional glycosylation sites thus shielding the binding site for the neutralizing antibodies.(10,37,39,44,56,69) Gain of an extra glycosylation site at spike region has been reported for P1 variant…”
BackgroundBroad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro
Zeng, L., Liu, Y., Wrynla, X. H., Abbott, T. R., Han, M., Zhu, Y., Chemparathy, A., Lin, X., Chen, X., Wang, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30546-7 · Cited by 54
SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
Singh, D. D., Parveen, A., & Yadav, D. K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.777212 · Cited by 58
Rapid characterization of spike variants via mammalian cell surface display
Javanmardi, K., Chou, C., Terrace, C. I., Annapareddy, A., Kaoud, T. S., Guo, Q., Lutgens, J., Zorkic, H., Horton, A. P., Gardner, E. C., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.024 · Cited by 56
D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity
Bhattacharya, M., Chatterjee, S., Sharma, A. R., Agoramoorthy, G., & Chakraborty, C. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11676-2 · Cited by 56
Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants
Ghimire, D., Han, Y., & Lu, M. (2022) · Viruses · doi:10.3390/v14061255 · Cited by 45
COVID‐19: A systematic review and update on prevention, diagnosis, and treatment
Aliabadi, H. A. M., Eivazzadeh‐Keihan, R., Parikhani, A. B., Mehraban, S. F., Maleki, A. R., Fereshteh, S., Bazaz, M., Zolriasatein, A., Bozorgnia, B., Rahmati, S., et al. (2022) · MedComm · doi:10.1002/mco2.115 · Cited by 52
Choudhary, M. C., Chew, K. W., Deo, R., Flynn, J. P., Regan, J., Crain, C. R., Moser, C., Hughes, M. D., Ritz, J., Ribeiro, R. M., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01254-1 · Cited by 69
“We assessed the presence of previously confirmed bamlanivimab resistance mutations (L452R, E484K, E484Q, F490S and S494P) 7,12 .”
BackgroundLaurini, E., Marson, D., Aulic, S., Fermeglia, A., & Pricl, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-99827-3 · Cited by 48
Metadata
- Authors
- McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Sprouse, K. R., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., Guastalla, S. B., Bona, G., Pellanda, A. F., Garzoni, C., Van Voorhis, W. C., Rosen, L. E., Snell, G., Telenti, A., Virgin, H. W., Piccoli, L., Corti, D., & Veesler, D.
- Affiliations
- University of Washington (US)
- Vir Biotechnology (Switzerland) (CH)
- Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
- VIR Biotechnology (United States) (US)
- Vir Biotechnology, San Francisco, CA 94158, USA.
- Independent physician, 6828 Balerna, Switzerland.
- Clinica Luganese Moncucco (CH)
- Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
- Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
- Corresponding author
- McCallum, Matthew
- Bassi, Jessica
- Chen, Alex
- Walls, Alexandra C.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- ORCID
- McCallum, Matthew
- Bassi, Jessica
- De Marco, Anna
- Chen, Alex
- Walls, Alexandra C.
- Di Iulio, Julia
- Tortorici, M. Alejandra
- Navarro, Mary-Jane
- Saliba, Christian
- Sprouse, Kaitlin R.
- Pinto, Dora
- Culap, Katja
- Bianchi, Siro
- Jaconi, Stefano
- Cameroni, Elisabetta
- Bowen, John E.
- Tilles, Sasha W.
- Pizzuto, Matteo Samuele
- Guastalla, Sonja Bernasconi
- Bona, Giovanni
- Pellanda, Alessandra Franzetti
- Garzoni, Christian
- Van Voorhis, Wesley C.
- Rosen, Laura E.
- Snell, Gyorgy
- Telenti, Amalio
- Virgin, Herbert W.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- Venue
- Science
- Published
- 2021-08-06
- Volume
- 373
- Issue
- 6555
- Pages
- 648-654
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9835956
- OpenAlex
- W3174747632
- Cited by
- 412
- References
- 90
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 25 · 2023: 56 · 2022: 165 · 2021: 141
- FWCI
- 31.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (DP1AI158186, HHSN272201700059C, U01 AI151698-01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, immune evasion, spike protein mutations, L452R, N-terminal domain, receptor binding domain, neutralizing antibodies, monoclonal antibodies, signal peptide cleavage site, disulfide bonds, mRNA vaccines, convalescent plasma, neutralization titers
- MeSH terms
- Protein Domains, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Antibodies, Monoclonal, Antibodies, Viral, Antigens, Viral, Humans, Models, Molecular, Mutation, Neutralization Tests, Protein Conformation, Amino Acid Substitution, Cryoelectron Microscopy, Protein Subunits, Protein Interaction Domains and Motifs, Immune Evasion, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.